| Summary: | Lauren C Magee,1 Mariam Louis,2 Vaneeza Khan,3 Lavender Micalo,3 Nauman Chaudary3 1Department of Pharmacy, Virginia Commonwealth University Health System, Richmond, VA, USA; 2Department of Pulmonary, Critical Care and Sleep Medicine, University of Florida, Jacksonville, FL, USA; 3Division of Pulmonary Disease and Critical Care Medicine, Department of Medicine, Virginia Commonwealth University, Richmond, VA, USACorrespondence: Lauren C Magee; Nauman ChaudaryVCU Adult Cystic Fibrosis Center, Division of Pulmonary Disease and Critical Care Medicine, 1200 East Broad Street, Box 980050, Richmond, VA, 23298, USATel +1 804 628-5046; +1 804 828-1579Fax +1 804 828-2578Email lauren.magee@vcuhealth.org; nauman.chaudary@vcuhealth.orgAbstract: Cystic Fibrosis (CF) is an autosomal recessive disease characterized by a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Impairment of the CFTR protein in the respiratory tract results in the formation of thick mucus, development of inflammation, destruction of bronchial tissue, and development of bacterial or fungal infections over time. CF patients are commonly colonized and/or infected with fungal organisms, Candida albicans or Aspergillus fumigatus, with prevalence rates ranging from 5% to 78% in the literature. Risk factors for acquiring fungal organisms include older age, coinfection with Pseudomonas aeruginosa, prolonged use of oral and inhaled antibiotics, and lower forced expiratory volume (FEV1). There are limited data available to differentiate between contamination, colonization, and active infection. Furthermore, the pathogenicity of colonization is variable in the literature as some studies report a decline in lung function associated with fungal colonization whereas others showed no difference. Limited data are available for the eradication of fungal colonization and the treatment of active invasive aspergillosis in adult CF patients. In this review article, we discuss the challenges in clinical practice and current literature available for laboratory findings, clinical diagnosis, and treatment options for fungal infections in adult CF patients.Keywords: cystic fibrosis, fungal infection, colonization, Candida, Aspergillus, ABPA, Aspergillus bronchitis
|
|---|
